BINV Stock Overview
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BINV from our risk checks.
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr23.95 |
| 52 Week High | kr30.00 |
| 52 Week Low | kr14.00 |
| Beta | 0.33 |
| 1 Month Change | 46.04% |
| 3 Month Change | 44.10% |
| 1 Year Change | -18.54% |
| 3 Year Change | -51.85% |
| 5 Year Change | -30.58% |
| Change since IPO | -98.19% |
Recent News & Updates
Recent updates
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
Apr 09
Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Sep 01Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive
Jun 02Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week
Feb 25We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely
Sep 28Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook
Aug 31Shareholder Returns
| BINV | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 30.0% | -1.2% | -0.7% |
| 1Y | -18.5% | -5.1% | 8.7% |
Return vs Industry: BINV underperformed the Swedish Biotechs industry which returned -6.3% over the past year.
Return vs Market: BINV underperformed the Swedish Market which returned 8.1% over the past year.
Price Volatility
| BINV volatility | |
|---|---|
| BINV Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BINV's share price has been volatile over the past 3 months.
Volatility Over Time: BINV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 111 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| BINV fundamental statistics | |
|---|---|
| Market cap | kr1.58b |
| Earnings (TTM) | -kr330.30m |
| Revenue (TTM) | kr71.46m |
22.1x
P/S Ratio-4.8x
P/E RatioIs BINV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINV income statement (TTM) | |
|---|---|
| Revenue | kr71.46m |
| Cost of Revenue | kr0 |
| Gross Profit | kr71.46m |
| Other Expenses | kr401.77m |
| Earnings | -kr330.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | -5.02 |
| Gross Margin | 100.00% |
| Net Profit Margin | -462.22% |
| Debt/Equity Ratio | 0% |
How did BINV perform over the long term?
See historical performance and comparison